No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AGEN240621P16000
- 0.80
- +0.27+50.94%
15min DelayClose Jun 13 16:00 ET
0.80High0.80Low
0.80Open0.53Pre Close1 Volume22 Open Interest16.00Strike Price80.00Turnover104.72%IV5.00%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.80Extrinsic Value100Contract SizeAmericanOptions Type-0.4657Delta0.1570Gamma16.00Leverage Ratio-0.0611Theta-0.0018Rho-7.45Eff Leverage0.0096Vega
Intraday
- 5D
- 1D
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) s
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial results.Core & Main posted quarterly earnings of 49 cents per share,
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 20 points on Tuesday.Shares of Saia Inc (NASDAQ:SAIA) rose sharply during today's pre-market trading session after the company reported
Agenus Announces Virtual Annual Shareholders Meeting
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $42
B.Riley Financial analyst Mayank Mamtani maintains $Agenus(AGEN.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 26.2% and a
Comments
So $Agenus(AGEN.US$ owner bought shares at some low price at 0.6, then the price went down to 0.3 then reverse split.
Now the price is $15.00. Sometimes things get worse before it get better.
You could be a day trader and make your profit or cut losses or an investor and hold on.
I see some possibilities in this company and reverse split is to consolidate compliance. Now the ethics of the management or if they consider investor or shareholder investment is another d...
Now the price is $15.00. Sometimes things get worse before it get better.
You could be a day trader and make your profit or cut losses or an investor and hold on.
I see some possibilities in this company and reverse split is to consolidate compliance. Now the ethics of the management or if they consider investor or shareholder investment is another d...
2
$Agenus(AGEN.US$ Reuters· 5 mins ago
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
$Agenus(AGEN.US$ I knew the momentum wouldn't last.
Read more